ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study.

    This is a double-blind, randomised, clinical trial with a 2-month treatment duration with 2 arms (1 active ingredient arm and 1 placebo arm). Participants will be recruited from databases and public media outlets. Following preliminary screening via telephone, potential participants will attend the clinic for an information session and will be required to provide their consent for inclusion in the trial. Consenting participants will undergo a health assessment including lifestyle, current medications and medical history; this data will be used for the comprehensive screening and to provide contextual data for the study. Once enrolled in the trial, participants will be randomly allocated to either the placebo group or the active intervention groups. Briefly, participants will have baseline measurements performed and receive a 2-month supply of the study product. Baseline testing includes: several questionnaires (Pittsburgh sleep quality survey, Epworth sleepiness scale, PROMIS sleep disturbance, self-assessment of sleep quality, Consensus sleep diary, SF-36, GI tolerance), anthropometry measures (weight, height, BMI, waist/hip circumference), 20 mL blood sample (TNF-a, IL-6, IL-8, IL-10, hs-CRP, PEA concentration, ELF/T) and wrist actigraphy (3 days wearing a Polar A370). Participants will be asked to consume the allocated product according to the dose prescribed (350 mg/day PEA or placebo). An opaque bottle containing opaque vegetable capsules will be provided to each participant according to their group allocation. Participants will then return at timepoint: 8 weeks for subsequent testing. At the 8-week time points, the testing will be a repeat of baseline measurements. At 5 days, 2 and 4 weeks the participants will complete the same testing except for any blood markers and anthropometry measurements. Two weeks after treatment cessation participants will be asked to complete questionnaires again online.

  • The role of motor cortices in motor imagery

    Motor imagery (MI) refers to the mental simulation of movement in the absence of overt movement. A strong body of evidence suggests that MI activates the human motor system in similar ways to actual movement. For example, the time taken to mentally simulate movement correlates with actual movement time, while there is considerable overlap in the neural systems activated during real and imagined movement. Interestingly, MI based interventions have shown moderate effect at improving motor ability in healthy adults (e.g. athletes) and patient groups (e.g. stroke). In some cases MI appears to be an effective adjunct to actual movement therapies for improving action efficiency. However, evidence as to the efficacy of MI therapies nonetheless remains mixed. Research, in large part, has attributed this to a poor understanding of the neural basis of MI. To this end, the putative role of important ‘motor’ structures such as the primary motor cortex (PMC) and the Supplementary motor cortices (SMA) remain debated. Clarifying the role of the PMC and SMA in MI is critical to developing a unified account of motor control, and the development of effective interventions for those with motor difficulties. Aim: The proposed study will aim to clarify the role of the PMC and SMA in MI in samples of young adults (18 to 35 years) with and without movement problems.

  • Does integrating a parenting support program into paediatric eczema care services improve treatment outcomes? A randomised controlled trial.

    Childhood eczema places an enormous burden on children and families. While good evidence for therapeutic interventions exists, ongoing non-compliance with treatment is common and presents a serious problem, increasing morbidity and impacting quality of life for children and families. Existing approaches have a record of failure in improving adherence. This study will improve clinical outcomes for children with eczema by integrating evidence-based support for parents who rely on existing eczema care services, to improve treatment adherence, reduce disease severity, and improve the quality of life for affected children. A randomised controlled trial will evaluate a brief parenting skills-training program for parents of children with eczema, comparing the intervention with usual care. We expect that this approach, which aims to enhance parental self-efficacy via application of practical parenting skills, will lead to improvements in adherence with medical treatment regimens and better disease control.

  • Promoting suicide prevention action planning in the community: A randomised controlled trial guided by the Bystander Intervention Model

    PURPOSE: To compare the efficacy of Bystander Intervention Model-informed suicide prevention material with standard existing material in promoting appropriate suicide risk assessment and protective action in the general community according to best-practice to suicide prevention. HYPOTHESES: 1. The experimental condition will have a significantly higher suicide risk assessment ability score than the standard condition. 2. The experimental condition will have a significantly higher suicide protective action ability score than the standard condition.

  • Suicide Prevention Education for the Public: How effective is Addressing the Bystander Effect through the Bystander Intervention Model in increasing knowledge, confidence and intent to intervene?

    PURPOSE: The aim of the study is to evaluate whether a BIM-guided factsheet about suicide prevention can improve participants’ knowledge, confidence and intent to intervene more than a standard condition when presented with a peer at risk of suicide. HYPOTHESIS: A public suicide prevention strategy which addresses the BIM will be more effective at increasing knowledge, confidence and intent to intervene when presented with someone at risk of suicide than a standard condition which does not address the BIM.

  • Study to evaLuate the Effect of trEating obstructive sleeP apnoea on coronary atherosclerosis with Computed Tomography (SLEEP-CT)

    Several factors link OSA and atherosclerosis, including metabolic abnormalities, activation of inflammatory and oxidative pathways, autonomic dysfunction and mechanical factors linked to snoring. However, the relationship between OSA and its treatment with the burden and progression of atherosclerotic plaque has not been systematically investigated. Advances in computed tomography (CT) imaging permit noninvasive high-resolution plaque imaging, enabling characterisation of the factors driving disease progression. This study is an observational study of 75 adults to determine the relationship between OSA and its treatment with plaque burden, composition and progression. Imaging of the coronary arteries will be performed on a CT scanner at a baseline and 12 month follow-up visit. The baseline phase permits evaluation of the relationship between OSA and its severity with the extent, distribution and composition of plaque. The serial phase permits a real-world assessment of the impact of changes in OSA severity on plaque progression.

  • Using Molecular Plaque Imaging to Ascertain Cardiovascular Risk in Patients with Sleep Apnoea

    Increasing evidence suggests that sleep apnoea is an important factor driving CVD risk. Beyond worsening blood pressure and diabetes, sleep apnoea has direct adverse effects on blood vessels. In this study, we propose to employ a molecular imaging approach to investigate the impact of OSA on plaque activity. This study is a cross-sectional, observational study with the objective to ascertain the presence and extent of inflammatory activity of atherosclerotic plaque in patients with sleep apnoea. We will enroll 50 adults with obstructive sleep apnoea (OSA), 25 with mild OSA and 25 with moderate to severe OSA commencing continuous positive airways pressure (CPAP) therapy with either established atherosclerotic cardiovascular disease (ASCVD) or risk factors for ASCVD. A combined computed tomography (CT) and positron emission tomography (PET) scan will be performed following intravenous administration of is 18F-fluorodeoxyglucose (18F-FDG) which will enable measurement of inflammatory plaque activity. The findings will provide important information that may lead to the development of an important new marker to monitor reductions in CVD risk in sleep apnoea.

  • Buddy strap versus splint in adults with boxer's fracture

    Fifth metacarpal neck fracture is a condition commonly referred to hand therapists for management. The method of treatment provided, as well as the frequency and duration of treatment vary widely, due to a lack of conclusive research evidence. This project will determine which of two treatment methods commonly employed by hand therapists is the most effective for the management of fifth metacarpal neck fracture. The findings of this project will enable therapists to decide with confidence which treatment method will produce the most satisfactory functional outcome and is preferred by patients. The results are expected to have implications for decision making about the resources allocated to this condition in the future, both in terms of therapist’s time and expertise, as well as materials used.

  • The BioHeart Study: assessing patients with suspected cardiovascular disease for new disease markers and risk factors

    For many diseases, researchers have been able to find ‘biomarkers’ that are in the blood and that can predict whether or not someone is at risk of getting the disease. Biomarkers are naturally occurring molecules, genes, or other characteristics that help us to identify diseases and disease processes. The purpose of the research project is to use blood and tissue from people with susceptibility or resilience to cardiovascular disease (CVD), and to try and find new biomarkers that can identify risk of CVD at an early stage. In addition, we will investigate the use of biomarkers that we have already identified, and their ability to predict events and outcomes. We hope that by doing this, we will be able to: 1. Find out more about how and why CVD occurs 2. Find out more about the way that CVD progresses and affects different people 3. Find new biomarkers that will help us to work out if someone is at risk of CVD earlier 4. Find new treatments for CVD

  • Is platelet-rich plasma (a blood product) helpful in treating lichen sclerosus on the vulva (external female genitalia)?

    This is a randomised control trial to compare platelet-rich plasma (PRP) against placebo (normal saline) as a treatment for women with symptomatic vulval lichen sclerosus (LS). LS is an acute and often chronic inflammatory dermatosis with autoimmune pathogenesis (Neill et al., 2010). It is a debilitating condition with serious consequences for the patient’s physical, emotional and sexual health (Newman et al., 2015). The management of LS is aimed at controlling symptoms, mainly severe vulvo-vaginal pruritus. Some women with LS are either unresponsive to corticosteroids or hesitate to use them. There are small studies to demonstrate PRP can improve vulvar LS. Therefore, this study is to assess the efficacy of PRP for treatment of vulvar LS.

Tags:
  • Finding clinical trials